Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSILODAC: Psilocybin for Treatment-Resistant Depression
NCT06650800Completed
- Sponsor
- CHU Nîmes
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by CHU Nîmes. Primary endpoint: Activity of the neural circuits responsible for the evaluation of effort at Day 5. Started Nov 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06650800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650800.